# Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

> **NCT03853694** · PHASE4 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 167 (actual)

## Conditions studied

- Elective Cesarean Section
- Pain Management

## Interventions

- **DRUG:** 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen
- **DRUG:** 150 mcg Duramorph + multi-modal pain regimen
- **DRUG:** Exparel TAP + multi-modal pain regimen

## Key facts

- **NCT ID:** NCT03853694
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-04
- **Primary completion:** 2020-01-09
- **Final completion:** 2020-01-16
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03853694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03853694, "Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03853694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*